← Leaderboards
Biju Parekkadan
Massachusetts General Hospital
$9,663,657
Attributed
$13,232,001
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,232,001 · 8
By mechanism
R01$9,913,497 · 3
T32$900,491 · 1
R44$773,285 · 1
K01$682,047 · 1
R43$499,306 · 1
R21$463,375 · 1
Top collaborators
- Korkut Uygun7 shared
- Curtis Lisante Cetrulo4 shared
- Harry Benjamin Larman4 shared
- Kibum Lee3 shared
- Arno W Tilles3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Korkut Uygun$11,870,153
- Iain A. Drummond$18,307,587
- Curtis Lisante Cetrulo$1,349,065
- Patrick Thomas Ellinor$17,149,392
- Vivek Y Reddy$1,256,865
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMonitorEngraftmentBaseTransplantationPharmaceutical PreparationsTissuesProtocols DocumentationStem CellsDesignOrganTranslatingBone MarrowTechnologyEngineeringProteinsIn VitroChronicAnimalsImageProceduresIn VivoCell TherapySite
Grant awards (34)
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$627,238
R01 · FY2025 · EB
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$449,944
R01 · FY2024 · EB
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$459,128
R01 · FY2023 · EB
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$459,128
R01 · FY2022 · EB
Postdoctoral Training for Translating Research in Regenerative Medicine$254,257
T32 · FY2022 · EB
Artificial, Humanized Stem Cell Niches$542,171
R01 · FY2021 · EB · contact PI
Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation$476,128
R01 · FY2021 · EB
A Functional genomics platform with integrated library cloning and molecular display$350,603
R01 · FY2021 · GM
Postdoctoral Training for Translating Research in Regenerative Medicine$177,855
T32 · FY2021 · EB
Artificial, Humanized Stem Cell Niches$553,236
R01 · FY2020 · EB · contact PI
Postdoctoral Training for Translating Research in Regenerative Medicine$468,379
T32 · FY2020 · EB
A Functional genomics platform with integrated library cloning and molecular display$349,842
R01 · FY2020 · GM
Artificial, Humanized Stem Cell Niches$544,399
R01 · FY2019 · EB · contact PI
A Functional genomics platform with integrated library cloning and molecular display$349,106
R01 · FY2019 · GM
Theranostic approach to transplant rejection using engineered cell biosensors$210,625
R21 · FY2019 · AI · contact PI
Artificial, Humanized Stem Cell Niches$559,849
R01 · FY2018 · EB · contact PI
A Functional genomics platform with integrated library cloning and molecular display$364,338
R01 · FY2018 · GM
Theranostic approach to transplant rejection using engineered cell biosensors$252,750
R21 · FY2018 · AI · contact PI
Artificial, Humanized Stem Cell Niches$51,742
R01 · FY2017 · EB · contact PI
Artificial, Humanized Stem Cell Niches$681,859
R01 · FY2016 · EB · contact PI
Artificial, Humanized Stem Cell Niches$668,221
R01 · FY2015 · EB · contact PI
Artificial, Humanized Stem Cell Niches$602,275
R01 · FY2014 · EB · contact PI
Peripheral Tissue Antigen Display by Mesenchymal Stem Cells$130,572
K01 · FY2014 · DK · contact PI
Artificial, Humanized Stem Cell Niches$582,897
R01 · FY2013 · EB · contact PI
Cellular Device for the Treatment of Acute Liver Failure$191,418
R43 · FY2013 · DK
Peripheral Tissue Antigen Display by Mesenchymal Stem Cells$137,970
K01 · FY2013 · DK · contact PI
Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure$773,285
R44 · FY2012 · DK
Artificial, Humanized Stem Cell Niches$572,709
R01 · FY2012 · EB · contact PI
Cellular Device for the Treatment of Acute Liver Failure$307,888
R43 · FY2012 · DK
Peripheral Tissue Antigen Display by Mesenchymal Stem Cells$137,970
K01 · FY2012 · DK · contact PI
Artificial, Humanized Stem Cell Niches$1,669
R01 · FY2012 · EB · contact PI
Artificial, Humanized Stem Cell Niches$667,015
R01 · FY2011 · EB · contact PI
Peripheral Tissue Antigen Display by Mesenchymal Stem Cells$137,970
K01 · FY2011 · DK · contact PI
Peripheral Tissue Antigen Display by Mesenchymal Stem Cells$137,565
K01 · FY2010 · DK · contact PI